Search clinical trials for: Pembrolizumab

Total 2258 results

Prof. Dr. med. Dirk Schadendorf

Completed

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (IMMU-TARGET)

Malignant Melanoma

Germany
Jair Bar, M.D., Ph.D.
Merck Sharp & Dohme LLC

Completed

Anti PD-1 Neo-adjuvant Treatment for NSCLC (MK3475-223)

Non Small Cell Lung Carcinoma | Stage II | Stage I

Israel
Sumitomo Pharma Oncology, Inc.
Syneos Health

Completed

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Neoplasms

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Cancer | Stage IV Lung Cancer

United States
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
Seagen Inc.

Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck | Urinary Bladder Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, Netherlands, Canada, Sweden
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Non Small Cell Lung Cancer

China
CORTESI LAURA

Unknown

Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)

Metastatic Breast Cancer
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Rahul Aggarwal
Merck Sharp & Dohme LLC; U.S. Army Medical Research and Development Command; Zenith...

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...

Recruiting

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)

Invasive Bladder Cancer

United Kingdom
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Lawrence Feldman, MD
Merck Sharp & Dohme LLC; HiberCell, Inc.

Active, not recruiting

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Non-Small Cell Lung Cancer

United States
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Adaptimmune

Withdrawn

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

United States
Amphivena Therapeutics, Inc.

Completed

Study of AMV564 in Patients With AML

Acute Myeloid Leukemia

United States
Southern Illinois University
Merck Sharp & Dohme LLC

Active, not recruiting

MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC)

Bladder Cancer

United States
Sun Yat-sen University

Unknown

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Renal Cancer Metastatic

China
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Prof. Dr. med. Christian Gratzke
Merck Sharp & Dohme LLC

Recruiting

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT)

Urologic Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate

Germany
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Merck Sharp & Dohme LLC

Terminated

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis

United States, Canada, Israel
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom

Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (PEACH)

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma

United Kingdom
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (PEMBRO-RT)

Non-Small Cell Lung Cancer

Netherlands
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Neoplasm

United States, Canada, Israel
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Yonsei University

Recruiting

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (GENUINE)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
University of California, San Francisco
National Cancer Institute (NCI); Prostate Cancer Foundation

Active, not recruiting

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Active, not recruiting

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Metastatic Melanoma | Stage IV Skin Melanoma | Stage IV Non-Small Cell Lung Cancer | Ocular Melanoma | Melanoma of Unknown Primary | Mucosal Melanoma | Metastatic Malignant Neoplasm in the Brain

United States
Shanghai Minimally Invasive Surgery Center

Recruiting

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Gastric Cancer Stage IIIB-IIIC

China
Yonsei University

Not yet recruiting

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer

United States
Henry Ford Health System

Recruiting

HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer

Head and Neck Neoplasms

United States
Sanford Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Combination With CRT for LA-SCCHN

Head and Neck Cancer | Laryngeal Cancer | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | Squamous Cell Carcinoma | Hypopharynx Cancer

United States
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States

Search clinical trials for: Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations